

MULTIPARAMETRIC STUDY OF CERTAIN TUMOR MARKERS IN BREAST CANCER

1290/12

Thesis

Submitted in Partial Fulfillment for the
Requirements of the M.D. Degree in (*Biochemistry*)

By

SANAA EISSA MOHAMED HAMED

Assistant Lecturer of Biochemistry

Faculty of Medicine, Ain Shams University

6/12.0/15
S.E

Supervised by

29/11/02

Dr. ALLI KHALIFA ALI

Professor of Biochemistry

Faculty of Medicine, Ain Shams University

Prof. FATHI TASH

Professor of Biochemistry

Faculty of Medicine, Ain Shams University

ABU BAKR EL SEDEEK

Professor of General Surgery

Faculty of Medicine, Ain Shams University

Prof. LAILA FARIS

Professor and Head of Radiotherapy Department

Faculty of Medicine, Ain Shams University

Biochemistry Department
Faculty of Medicine
Ain Shams University



1989



Approval Sheet

Approved by:

Prof. Dr. Khadiga Ghoneim

Khadiga Ghoneim

Prof. Dr. Mohamed Reda Hamza

Mohamed Reda Hamza

Prof. Dr. Ali Khalifa Ali

Ali Khalifa

Committe in charge

Date 3 / 5 / 1989



ACKNOWLEDGEMENT

First and foremost thanks to God

Before presenting this thesis, I wish to express my deepest gratitude to Prof. Ali Khalifa, Professor of Biochemistry and head of Oncology Diagnostic Unit, Ain Shams, Faculty of Medicine, for his great help starting from giving me the chance to work in this field, passing through many directions and valuable advices throughout the work and ending by his prominent finger prints during the finalization of this work. It is a great honour to work under his guidance and supervision.

I owe my thanks and appreciation to Professor Fathi Tash, Professor of Biochemistry, Ain Shams, Faculty of Medicine, who's ideas brought forward this subject. His continuous advice, encouragement, constant support and constructive criticism, made the completion of this work possible.

I am also very grateful to Prof. Abu Bakr El-Sedeek, Professor of Surgery, Ain Shams, Faculty of Medicine, for his ideal guidance and motivation. He was very helpful in dealing with patients.

I am thankful to Prof. Laila Faris, Professor and head of Radiotherapy Department, Ain Shams, Faculty of Medicine, who gave me the necessary support and provided me with her valuable assistance in monitoring breast cancer patients.

I am greatly indebted to Dr. Hafez Abdel Fatah, Lecturer of Biochemistry, Ain Shams Faculty of Medicine and Dr. Thanaa Helal, Lecturer of Pathology, Ain Shams, Faculty of Medicine who provided me with their valuable assistance in my laboratory research.

Last but not least, I wish to express my thanks to my husband, Dr. Omar El Almady, who helped me throughout the course of my work.

My thanks lastly go to all who helped and supported me in my work.

CONTENTS

AIM OF THE WORK	1
INTRODUCTION	3
* Epidemiology of Breast Cancer	3
* Histopathological Classification of Breast Cancer	4
* Grading of Carcinoma of the Breast	8
* Benign Breast Lesions	9
* The International Classification (TNM) of Breast Cancer	11
* Tumor Markers	14
- Definition	14
- Classification	14
- Clinical Application	16

REVIEW OF LITERATURE

* Estrogen receptor	19
- Introduction	19
- Biochemistry of ER	19
- The concept of ER and its Mode of Action	21
- Role of ER in Breast Cancer	21
- Role of ER in Endometrial Cancer	22
- Role of ER in Meningioma	23
- Methods for analyzing Steroid receptors in Human Breast Cancer	23
1. Assays Depending on the Binding Capacity of the receptor (Binding Assays)	25
2. Assays Depending on Immuno reactivity of ER	30
* CA 15-3	30
- Biochemistry	32
- Clinical Application	33
* Carcinoembryonic Antigen	35
- History and Biochemistry	35
- CEA Production and Metabolism	37
- Incidence of Elevation	39
- Value in Screening	40
- CEA in Breast Cancer	40
- CEA in Colon Cancer	42
- CEA in Bronchogenic Cancer	43

* Ferritin	44
- Biochemistry	44
- Clinical Application	45
- Ferritin In Breast Cancer	46
- Ferritin as a tumor marker in patients with Gynaecological Cancer	47
- Ferritin in Head in Neck Malignancies	47
- Ferritin in Hepatocellular Carcinoma	47
* Pregnancy Specific - B ₁ Glycoprotein (SP ₁)	48
- Physiocochemical Properties	48
- Biology	49
- Clinical Application	50

MATERIAL AND METHODS

* Material	52
* ER Assays	58
1. Biochemical Assay of ER in subcellular fractions	58
2. Immunocytochemical Assay	70
* Determination of CA153	75
* Determination of CEA	58
* Determination of Ferritin	81
* Determination of SP1	83
* Statistical analysis	86

RESULTS

DISCUSSION	165
------------	-----

SUMMARY AND CONCLUSION

189

REFERENCES

192

ARABIC SUMMARY

LIST OF TABLES

Table 1a	: Clinical data of breast cancer patients	52, 53, 54
Table 1b	: Clinical data of benign breast disease patients	56
Table 1c	: Data of controls	57
Table 2	: Scheme for breast tissue usage	59
Table 3	: Influence of cytosol protein concentration on ER assay	95
Table 4	: Influence of nuclear extract protein concentration on ER assay	95
Table 5	: Incidence of ER positivity in benign and malignant breast tumors	97
Table 6	: ER distribution in benign and malignant breast tumors	98
Table 7	: Distribution of ER N/C ratio in benign and malignant breast tumors in relation to menopausal status	101
Table 8	: Distribution of (ER +) tumors in breast cancer patients in relation to histologic type of the tumor	110
Table 9	: Distribution of (ER +) tumors in benign breast disease patients in relation to histologic type of the tumor	110
Table 10	: Distribution of (ER +) tumors in benign mammary lesions in relation to the degree of epithelial hyperplasia	112
Table 11	: Comparison between biochemical and immunocytochemical assay for detection of (ER +) tumors	112
Table 12	: CA 15.3 serum level in controls, patients with benign and malignant breast tumors	114

Table 13	: CEA serum level in controls, patient with benign and malignant breast tumors	123
Table 14	: Ferritin serum level in controls, patients with benign and malignant breast tumors	131
Table 15	: SP1 serum level in controls, patients with benign and malignant breast tumors	139
Table 16	: Positivity rate (%) of CA 15.3, CEA, ferritin and SP1 in breast cancer patients	147
Table 17	: Serum tumor marker CA15.3, CEA, ferritin and SP1 in the studied groups	147
Table 18	: Sensitivity and specificity rates of single marker: CA15.3, CEA, Ferritin, SP1 and marker combinations	148

LIST OF FIGURES

Fig. 1	: DNA standard curve.	64
Fig. 2	: Protein standard curve.	66
Fig. 3	: ER standard curve.	69
Fig. 4	: CA 15.3 standard curve.	77
Fig. 5	: CEA standard Curve.	80
Fig. 6	: SP ₁ standard curve.	85
Fig. 7	: Influence of storage temperature on ER assay.	92
Fig. 8	: Stability of ER at -180°C.	92
Fig. 9	: Influence of homogenization speed on ER assay.	93
Fig. 10	: Influence of room temperature on ER assay.	94
Fig. 11	: Influence of KCl concentration on ER-C assay.	96
Fig. 12	: Influence of KCl concentration on ER-N assay.	96
Fig. 13a	: Frequency of various ER combinations in breast cancer tumors.	99
Fig. 13b	: Frequency of various ER combinations in breast cancer tissues.	99
Fig. 14a	: Relationship between ER-C and ER-N in breast cancer patients.	
Fig. 14b	: Relationship between ER-C and ER-N in benign breast disease patients.	100
Fig. 15a	: Relationship between ER-C and age of the breast cancer patients.	102
Fig. 15b	: Relationship between ER-C and age of benign breast disease patients.	102
Fig. 16a	: Relationship between ER-N and age of breast cancer patients	103
Fig. 16b	: Relationship between ER-N and age of benign breast disease patients.	103
Fig. 17a	: Relationship between ER-T and age of breast cancer patients.	104
Fig. 17b	: Relationship between ER-T and age of benign breast disease patients.	104
Fig. 18a	: Relationship between ER N/C ratio and age of breast cancer patients.	105
Fig. 18b	: Relationship between ER-N/C ratio and age of benign breast disease patients.	105
Fig. 19	: Distribution of ER-C levels in benign and malignant breast tumors in relation to menopausal status.	106
Fig. 20	: Distribution of ER-N levels in benign and malignant breast tumors in relation to menopausal status.	106
Fig. 21	: Distribution of ER-T levels in benign and malignant breast tumors in relation to menopausal status.	106
Fig. 22	: ER-N/C ratio in benign and malignant tumors in relation to menopausal status.	107

Fig. 23	: ER-T values in benign and malignant breast tumors.	108
Fig. 24	: ER-T values in TNM classes of breast cancer tumors	109
fig. 25	: ER-T values in relation to histologic grade of breast cancer tumors	111
Fig. 26	: Immunohistochemical localization of estrogen receptor using monoclonal anti-human ER antibody	113
Fig. 27	: CA 15.3 values in controls, benign and breast cancer patients.	115
Fig. 28	: CA 15.3 values in controls, benign and TNM classes of breast cancer patients.	116
Fig. 29	: CA 15.3 serum concentration in dependence of tumor stage with the last two columns representing nodal stratification of stage I, II, and III.	117
Fig. 30	: Serum CA 15.3 in monitoring of stage I breast cancer patients.	119
Fig. 31	: Serum CA15.3 in monitoring of stage II breast cancer patients.	120
Fig. 32	: Serum CA 15.3 in monitoring of stage III breast cancer patients.	121
Fig. 33	: Serum CA15.3 in monitoring of stage IV breast cancer patients.	122
Fig. 34	: CEA values in controls, benign and breast cancer patients.	124
Fig. 35	: CEA values in controls, benign and TNM classes of breast cancer patients.	125
Fig. 36	: CEA serum concentration in dependence of tumor stage, with the last two columns representing nodal stratification of stage I, II and III.	126
Fig. 37	: Postoperative follow up of CEA in stage I breast cancer patients.	127
Fig. 38	: Postoperative follow up of CEA in stage II breast cancer patients.	128
Fig. 39	: Postoperative follow up of CEA in stage III breast cancer patients.	129
Fig. 40	: Postoperative follow up of CEA in stage IV breast cancer patients.	130
Fig. 41	: Ferritin values in controls, benign and breast cancer patients.	132
Fig. 42	: Ferritin values in controls, benign and TNM classes of breast cancer patients.	133
Fig. 43	: Ferritin serum concentration in dependence of tumor stage with the last two columns representing nodal stratification of stage I, II and III.	134
Fig. 44	: Serum ferritin in monitoring stage I breast cancer patients.	135

Fig. 45	: Serum ferritin in monitoring stage II breast cancer patients.	136
Fig. 46	: Serum ferritin in monitoring stage III breast cancer patients.	137
Fig. 47	: Serum ferritin in monitoring stage IV breast cancer patients.	138
Fig. 48	: SP1 values in controls, benign and breast cancer patients.	140
Fig. 49	: SP ₁ values in controls, benign and TNM classes of breast cancer patients.	
Fig. 50	: SP ₁ serum concentrations in relation to tumor stage with the last two columns representing nodal stratification of stage I, II and III.	142
Fig. 51	: Postoperative follow-up of SP ₁ in stage I breast cancer patients.	143
Fig. 52	: Postoperative follow-up of SP ₁ in stage II breast cancer patients.	144
Fig. 53	: Postoperative follow-up of SP ₁ in stage III breast cancer patients.	145
Fig. 54	: Postoperative follow-up of SP ₁ in stage IV breast cancer patients.	146
Fig. 55	: Tumor Markers time course in case (a) with primary breast cancer, T ₃ N ₁ M ₀	150
Fig. 56	: Tumor markers time course in case (b) with primary breast cancer, T ₄ N ₁ M ₀	151
Fig. 57	: Tumor markers time course in case (c) with primary breast cancer T ₃ N ₁ M ₀	153
Fig. 58	: Tumor markers time course in case (d) with primary breast cancer, T ₃ N ₁ M ₀	154
Fig. 59	: Tumor markers time course in case (e) with primary breast cancer, T ₁ N ₁ M ₁	155
Fig. 60	: Tumor markers time course in case (f) with bone metastases.	157
Fig. 61	: Tumor markers time course in case (g) with primary breast cancer, T ₄ N ₁ M ₀	158
Fig. 62	: Tumor markers time course in case (h) with primary breast cancer, T ₃ N ₁ M ₀	159
Fig. 63	: Tumor markers time course in case (i) with primary breast cancer, T ₄ N ₁ M ₀	161
Fig. 64	: Tumor markers time course in case (j) with primary breast cancer, T ₄ N ₁ M ₀	162
Fig. 65	: Tumor markers time course in case (k) with primary breast cancer, T ₄ N ₁ M ₀	164

List of abbreviations

Ab	: Antibodies
AFP	: Alphafetoprotein
AJC	: American Joint Committee for Cancer
APR	: Acute phase reactants
β-HCG	: Beta subunit of human chorionic gonadotropin
CA 15.3	: Cancer antigen 15.3
CA 19.9	: Cancer antigens 19.9
CA 125	: Cancer antigen 125
Car.	: Carcinoma
CBG	: Corticosteroid binding globulin
cDNA	: DNA coding sequence
CEA	: Carcinoembryonic antigen
CMF	: Cyclophosphamide, methotrexate, 5-fluoracil
DCC	: Dextran coated charcoal
DEAE	: diaminoethyl aminoethylene
d/s.	: Disease
DNA	: Deoxyribonucleic acid
EIA	: Enzymeimmunoassay
ELSA	: Enzyme linked immunosorbent assay
ER	: Estrogen receptor
ER-C	: Estrogen receptor in the cytosol
ER-EIA	: Estrogen receptor Enzymeimmunoassay
ER-ICA	: Estrogen receptor immunocytochemical assay
ER-N	: Estrogen receptor in nuclear extract
ER-T	: Total estrogen receptor
5AC	: 5-fluoracil, adriamycin, cyclophosphamide
GGT	: Gamma glutamyltransferase
H	: Heavy

HAP	: Hydroxylapatite
HCC	: Hepatocellular carcinoma
HPL	: Human placental lactogen
IDC	: Invasive duct carcinoma
ILC	: Invasive lobular carcinoma
I	: Light
M	: Molar
MAbs	: Monoclonal antibodies
MTGP	: Mammary tumor associated glycoprotein
OPD	: Orthophenylenediamine
PAP	: Peroxidase antiperoxidase
PAP	: Prostatic acid phosphatase
PBS	: Phosphate buffered saline
PgR	: Progesterone receptor
POA	: Pancreatic Oncofetal Antigen
SDS	: Sodium dodecyl sulfate
SHBG	: Sex hormone binding globulin
SP1	: Pregnancy specific β_1 glycoprotein
TNM	: T: tumor; N: lymph node; M: distant metastases
TPA	: Tissue polypeptide antigen
WHO	: World Health Organization
tries	: Secondaries
+	: Positive
-	: Negative

AIM OF THE WORK

The relatively long preclinical growth phase and tendency of breast cancer to metastasise have led many clinicians to believe that breast cancer is a systemic disease. Fifty percent of patients with breast cancer who undergo local surgical treatment will eventually die of metastatic disease, suggesting that the present methods of staging are inadequate, since presumably the patients had micrometastases at the time of their first presentation (*Giuliano, 1988*).

Consequently it would be useful to have indices that could assist clinicians in staging their patients more accurately before surgery, in particular, in delineation of those likely to have distant tumor spread at presentation. Biochemical tumor markers have been shown to be useful in detecting micrometastases in several tumors. These markers are defined as substances which can be measured quantitatively by biochemical or immunochemical means in tissues or body fluids to identify the presence of a tumor, possibly the organ where it resides, to establish the extent of tumor burden before treatment as well as monitor the response to therapy. With this definition, a wide variety of substances can be identified as tumor markers. These include tumor associated antigens, oncofetal antigens, enzymes, specific proteins, oncoplacental proteins, and steroid hormone receptors (*Schwartz, 1989*).

Tumor markers are presently being studied with great interest by clinical oncologists as they provide additional useful information to that furnished by conventional laboratory and instrumental diagnostic examinations. Their importance will definitively increase if their clinical